Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$161.53|
|52 Week High||US$161.10|
|52 Week Low||US$325.12|
|1 Month Change||-11.40%|
|3 Month Change||-35.32%|
|1 Year Change||-28.08%|
|3 Year Change||32.16%|
|5 Year Change||241.43%|
|Change since IPO||2,976.75%|
Recent News & Updates
|AMED||US Healthcare||US Market|
Return vs Industry: AMED underperformed the US Healthcare industry which returned 37.7% over the past year.
Return vs Market: AMED underperformed the US Market which returned 36.2% over the past year.
Stable Share Price: AMED is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AMED's weekly volatility (8%) has been stable over the past year.
About the Company
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Amedisys Fundamentals Summary
|AMED fundamental statistics|
Is AMED overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AMED income statement (TTM)|
|Cost of Revenue||US$1.19b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||7.55|
|Net Profit Margin||11.25%|
How did AMED perform over the long term?See historical performance and comparison
Is Amedisys undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMED ($161.53) is trading below our estimate of fair value ($220.07)
Significantly Below Fair Value: AMED is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMED is good value based on its PE Ratio (21.3x) compared to the US Healthcare industry average (22x).
PE vs Market: AMED is poor value based on its PE Ratio (21.3x) compared to the US market (17.7x).
Price to Earnings Growth Ratio
PEG Ratio: AMED is poor value based on its PEG Ratio (7.2x)
Price to Book Ratio
PB vs Industry: AMED is overvalued based on its PB Ratio (6x) compared to the US Healthcare industry average (3.2x).
How is Amedisys forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMED's forecast earnings growth (3% per year) is above the savings rate (2%).
Earnings vs Market: AMED's earnings (3% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: AMED's earnings are forecast to grow, but not significantly.
Revenue vs Market: AMED's revenue (9.6% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: AMED's revenue (9.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMED's Return on Equity is forecast to be low in 3 years time (18.7%).
How has Amedisys performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMED has high quality earnings.
Growing Profit Margin: AMED's current net profit margins (11.3%) are higher than last year (6.5%).
Past Earnings Growth Analysis
Earnings Trend: AMED's earnings have grown significantly by 36.9% per year over the past 5 years.
Accelerating Growth: AMED's earnings growth over the past year (92.7%) exceeds its 5-year average (36.9% per year).
Earnings vs Industry: AMED earnings growth over the past year (92.7%) exceeded the Healthcare industry 32.2%.
Return on Equity
High ROE: AMED's Return on Equity (28.4%) is considered high.
How is Amedisys's financial position?
Financial Position Analysis
Short Term Liabilities: AMED's short term assets ($391.0M) do not cover its short term liabilities ($449.2M).
Long Term Liabilities: AMED's short term assets ($391.0M) exceed its long term liabilities ($274.5M).
Debt to Equity History and Analysis
Debt Level: AMED's debt to equity ratio (21.4%) is considered satisfactory.
Reducing Debt: AMED's debt to equity ratio has reduced from 22.1% to 21.4% over the past 5 years.
Debt Coverage: AMED's debt is well covered by operating cash flow (144.5%).
Interest Coverage: AMED's interest payments on its debt are well covered by EBIT (29.9x coverage).
What is Amedisys's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMED's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMED's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMED's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMED's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMED's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Kusserow (60 yo)
Mr. Paul Berthold Kusserow has been the Chief Executive Officer of Amedisys, Inc since December 16, 2014 and served as its President since December 16, 2014 until February 18, 2021. He serves as Chairman a...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD6.36M) is about average for companies of similar size in the US market ($USD6.46M).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Experienced Management: AMED's management team is considered experienced (3.9 years average tenure).
Experienced Board: AMED's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AMED insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Amedisys, Inc.'s employee growth, exchange listings and data sources
- Name: Amedisys, Inc.
- Ticker: AMED
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$5.357b
- Shares outstanding: 32.63m
- Website: https://www.amedisys.com
Number of Employees
- Amedisys, Inc.
- 3854 American Way
- Suite A
- Baton Rouge
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 22:57|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.